Curated News
By: NewsRamp Editorial Staff
June 05, 2025
Nutriband Advances Safer Opioid Treatment with AVERSA Technology
TLDR
- Nutriband's AVERSA technology offers a competitive edge in the opioid treatment market with its innovative transdermal delivery system for buprenorphine, targeting peak sales of $70M – $130M.
- Nutriband is developing AVERSA Buprenorphine, a transdermal patch using proprietary technology to deliver medication for opioid use disorder and pain, aiming for FDA approval.
- Nutriband's AVERSA technology could significantly reduce opioid misuse, offering a safer treatment option and addressing a critical public health crisis.
- Discover how Nutriband's AVERSA technology is revolutionizing opioid treatment with a transdermal patch that could change the landscape of pain and addiction therapy.
Impact - Why it Matters
The opioid epidemic remains a critical public health crisis, with millions affected by addiction and overdose deaths. Nutriband's development of abuse-deterrent opioid treatments like AVERSA(TM) Buprenorphine could revolutionize how these medications are administered, reducing the potential for misuse and offering a safer alternative for patients. This innovation not only addresses a significant unmet medical need but also has the potential to save lives and reduce the societal and economic burdens of opioid addiction.
Summary
Nutriband Inc. (NASDAQ: NTRB) is making strides in the fight against the opioid epidemic with its innovative AVERSA technology, aimed at delivering safer, abuse-deterrent treatments for opioid use disorder and chronic pain. The company is developing a transdermal delivery system for buprenorphine, an FDA-approved medication for treating opioid addiction, projected to achieve peak annual sales of $70M – $130M. Nutriband's AVERSA pipeline includes two key candidates: AVERSA(TM) Fentanyl and AVERSA(TM) Buprenorphine, both designed to offer safer alternatives to traditional opioid therapies. This development comes at a critical time as the demand for innovative solutions to the opioid crisis grows. For more details, visit Read More>>.
Nutriband's efforts are part of a broader initiative to address the opioid epidemic, a pressing public health crisis. The company's proprietary Aversa technology represents a significant advancement in the field of transdermal pain and addiction treatments, offering hope for safer administration methods. Investors and stakeholders can stay updated on Nutriband's progress through the company's newsroom at https://ibn.fm/NTRB. BioMedWire, a specialized communications platform, highlights these developments, emphasizing the importance of innovative solutions in the biotechnology and life sciences sectors.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Nutriband Advances Safer Opioid Treatment with AVERSA Technology
